FY2026 EPS Estimates for Amgen Boosted by Erste Group Bank

Amgen Inc. (NASDAQ:AMGN) – Equities researchers at Erste Group Bank lifted their FY2026 earnings per share (EPS) estimates for Amgen in a note issued to investors on Thursday, August 27th. Erste Group Bank analyst H. Engel now forecasts that the medical research company will earn $23.05 per share for the year, up from their prior estimate of $22.41. Erste Group Bank has a “Hold” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $22.97 per share.

A number of other brokerages also recently issued reports on AMGN. Barclays raised their price objective on Amgen from $360.00 to $380.00 and gave the stock an “equal weight” rating in a research report on Friday, August 14th. Citigroup upped their target price on shares of Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Guggenheim lifted their price target on shares of Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a research report on Monday, August 10th. Finally, Canaccord Genuity Group lifted their price target on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $380.43.

Amgen Stock Performance

Shares of Amgen stock opened at $438.12 on Monday. Amgen has a 52 week low of $269.77 and a 52 week high of $447.03. The business’s fifty day simple moving average is $392.17 and its 200-day simple moving average is $365.59. The firm has a market cap of $236.86 billion, a PE ratio of 27.23, a price-to-earnings-growth ratio of 3.10 and a beta of 0.43. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter last year, the firm earned $6.02 earnings per share. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AMGN. Anfield Capital Management LLC grew its stake in shares of Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares in the last quarter. Dogwood Wealth Management LLC increased its position in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the period. Tower View Wealth Management LLC increased its position in shares of Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after acquiring an additional 63 shares during the period. Manning & Napier Advisors LLC raised its stake in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Evergreen Advisors LLC acquired a new stake in shares of Amgen in the first quarter valued at $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock valued at $2,540,926 over the last 90 days. 0.85% of the stock is currently owned by company insiders.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s dividend payout ratio is presently 62.65%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Repatha delivers potentially market-expanding cardiovascular data. Amgen reported that Repatha (evolocumab) reduced the risk of death by 20% in more than 12,000 high-risk patients who had not previously suffered a heart attack or stroke. The Phase 3 VESALIUS-CV findings could support broader use of the cholesterol drug, increase physician adoption and strengthen one of Amgen’s key revenue drivers. Amgen Repatha clinical results
• Positive Sentiment: Analysts are raising earnings expectations. Erste Group Bank increased its FY2027 EPS forecast to $24.43 from $23.50, above the broader consensus estimate of $22.97. The revision follows Amgen’s recent quarterly earnings and revenue beat, along with higher full-year guidance, reinforcing the company’s favorable earnings momentum. Erste Group Bank earnings forecast
• Positive Sentiment: Investor attention is increasing around Amgen’s cardiovascular opportunity. Jim Cramer highlighted Repatha as a largely overlooked drug that could address a very large market, potentially comparable in importance to major obesity-drug markets over time. While this is commentary rather than a fundamental forecast, it adds to the bullish narrative surrounding Repatha. Jim Cramer on Amgen’s Repatha opportunity
• Neutral Sentiment: Relative performance remains favorable, but valuation is being debated. Reports note that AMGN has outperformed the broader market and other general drug manufacturers, while analysts remain moderately bullish. However, the stock’s strong run and elevated valuation could limit additional upside unless earnings and product growth continue to accelerate. Amgen stock performance compared with drug manufacturers
• Negative Sentiment: UK regulators suspended Tavneos for new patients. Britain’s medicines regulator cited unreliable data from the main study supporting approval of the rare-disease drug and suspended its use and sale for new patients. The action creates regulatory, reputational and potential revenue risks, although Tavneos is smaller than Amgen’s major commercial products. UK regulator Tavneos suspension

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.